Guidelines and quality for community-acquired pneumonia: Measures from the joint commission and the centers for medicare and medicaid services

American Journal of Health-System Pharmacy

Volumn 66, Issue 12 SUPPL. 4, 2009, Pages

  Shorr, Andrew F ^a   Owens Jr , Robert C ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

Antiinfective agents; Centers for Medicare and Medicaid Services; Community acquired infections; Compliance; Immunization; Infectious Diseases Society of America; Joint Commission on Accreditation of Healthcare Organizations; Pneumococcal infections; Pneumococcal vaccines; Pneumonia; Protocols; Quality assurance; Vaccines

Indexed keywords

AMIKACIN; AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GEMIFLOXACIN; GENTAMICIN; IMIPENEM; INFLUENZA VACCINE; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; OXYGEN; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; VACCINE;

ANTIMICROBIAL THERAPY; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; EMERGENCY WARD; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; IMMUNOCOMPETENCE; INFLUENZA; INFLUENZA VACCINATION; INTENSIVE CARE UNIT; MEDICAID; MEDICAL SOCIETY; MEDICARE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT OUTCOME; ACCREDITATION; ARTICLE; COMMUNICABLE DISEASE; GOVERNMENT; HEALTH CARE QUALITY; PNEUMONIA; REIMBURSEMENT; UNITED STATES;

ANTI-BACTERIAL AGENTS; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); COMMUNITY-ACQUIRED INFECTIONS; GUIDELINE ADHERENCE; HUMANS; JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGANIZATIONS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; REIMBURSEMENT, INCENTIVE; UNITED STATES; VACCINES, CONJUGATE;

EID: 68849091087     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/090087a     Document Type: Conference Paper

References (36)

1. Marrie TJ. Infectious disease of the respiratory tract. N Engl J Med. 1998; 339: 1336-7.
2. Nawar EW, Niska RW, Xu J. National Hospital Ambulatory Medical Care Survey: 2005 emergency department summary. Adv Data. 2007; 386:1-32.
3. Healthcare Cost and Utilization Project Nationwide Inpatient Sample 2006. http://hcupnet.ahrq.gov (accessed 2008 Aug 12).
4. Houck PM, Bratzler DW, Nsa W et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004; 164:637-44.
5. Centers for Medicare and Medicaid Services, the Joint Commission. Specification Manual for National Hospital Quality Measures, www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/ Current+NHQM+Manual.htm (accessed 2009 Feb 19).
6. Meehan TP, Fine MJ, Krumholz HM et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA. 1997; 278:2080-4. (Pubitemid 28016230)
7. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44:159-77. (Pubitemid 46084814)
8. Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006; 4:36-45.
9. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005; 365:579-87. (Pubitemid 40247914)
10. Bergman M, Huikko S, Huovinen P et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006; 50:3646-50. (Pubitemid 44684876)
11. Hecker MT, Aron DC, Patel NP et al. Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antian-aerobic spectrum of activity. Arch Intern Med. 2003; 163:972-8.
12. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416. (Pubitemid 40227463)
13. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44(suppl 2):S27-72.
14. American College of Emergency Physicians Policy Committee. Clinical policy for the management and risk stratification of community-acquired pneumonia in adults in the emergency department. Ann Emerg Med. 2001; 38:107-13.
15. Bodi M, Rodriguez A, Sole-Violan J et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis. 2005; 41:1709-16. (Pubitemid 41759852)
16. Wu JH, Howard DH, McGowan JE Jr et al. Adherence to infectious diseases society of America guidelines for empiric therapy for patients with community-acquired pneumonia in a commercially insured cohort. Clin Ther. 2006; 28:1451-61.
17. Castella A, Charrier L, Di Legami V et al. Surgical site infection surveillance: analysis of adherence to recommendations for routine infection control practices. Infect Control Hosp Epidemiol. 2006; 27:835-40. (Pubitemid 44320335)
18. Menendez R, Torres A, Zalacain R et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med. 2005; 172:757-62. (Pubitemid 41324232)
19. Public reporting of measure. Joint Commission on the Accreditation of Healthcare Organizations, www.jointcommission.org/qualitycheck/sip-2.htm (accessed 2007 Nov 19).
20. Kyaw MH, Lynfield R, Schaffher W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006; 354:1455-63.
21. Johnstone J, Marrie TJ, Eurich DT et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007; 167:1938-43. (Pubitemid 47606632)
22. Metersky ML, Ma A, Bratzler DW et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004; 169:342-7. (Pubitemid 38134812)
23. Mokdad AH, Marks JS, Stroup DF et al. Actual causes of death in the United States, 2000. JAMA. 2004; 291:1238-45. (Pubitemid 38541668)
24. Mitka M. JCAHO tweaks emergency departments' pneumonia treatment standards. JAMA. 2007; 297:1758-9. (Pubitemid 46658663)
25. Kanwar M, Brar N, Khatib R et al. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest. 2007; 131:1865-9. (Pubitemid 46981647)
26. Metersky ML, Sweeney TA, Getzow MB et al. Antibiotic timing and diagnostic uncertainty in Medicare patients with pneumonia: is it reasonable to expect all patients to receive antibiotics within 4 hours? Chest. 2006; 130:16-21.
27. Tellado JM, Sen SS, Caloto MT et al. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand J Infect Dis. 2007; 39: 947-55.
28. Bare M, Castells X, Garcia A et al. Importance of appropriateness of empiric antibiotic therapy on clinical outcomes in intra-abdominal infections. Int J Technol Assess Health Care. 2006; 22:242-8.
29. Sturkenboom MC, Goettsch WG, Picelli G et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol. 2005; 60:438-43. (Pubitemid 41428476)
30. Krobot K, Yin D, Zhang Q et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004; 23:682-7. (Pubitemid 39304322)
31. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis. 2005; 11:802-7.
32. Critchley IA, Brown SD, Traczewski MM et al. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. Antimicrob Agents Chemother. 2007; 51: 4382-9.
33. Iannini PB, Paladino JA, Lavin B et al. A case series of macrolide treatment failures in community acquired pneumonia. J Chemother. 2007; 19:536-45. (Pubitemid 350177965)
34. Mazzariol A, Koncan R, Vitali LA et al. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin- susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. J Antimicrob Chemother. 2007;59:1171-6. (Pubitemid 47073329)
35. Baiter M, Weiss K. Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones? Can Fam Physician. 2006; 52:1236-42. (Pubitemid 44967300)
36. Nichol KL, Nordin JD, Nelson DB et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med. 2007; 357:1373-81. (Pubitemid 47535592)